Talimogene Laherparepvec: A groundbreaking viral therapy for late stage melanoma

From MicrobeWiki, the student-edited microbiology resource
Revision as of 23:42, 25 April 2018 by Faziolia (talk | contribs)
Jump to: navigation, search
This is a curated page. Report corrections to Microbewiki.

Classification

Baltimore classification: dsDNA
Family: Herpesviridae
Virion: Enveloped
Capsid symmetry: Icosahedral
Replication site: Nucleus and cytoplasm

Overview of Talimogene Laherparepvev (T-VEC)

Figure 1: Transmission Electron Micrograph of a Herpes Simple Virus Particle by Jay C. Brown of the University of Virginia. [http://darwin.bio.uci.edu/~faculty/wagner/hsv2f.html.


Figure 2: Image of the local and systemic effects of T-VEC. The local impact of T-VEC includes replication within cancer cells and release of virus particles upon cell lysis. The systemic impact of T-VEC includes the release of tumor specific antigens and the activation of Dendritic cells by GM-CSF. [9][https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519012/pdf/nihms709872.pdf
Figure 3: Image of the results from the Phase II and III T-VEC studies. The results shown include the number of patients, the stage of their melanoma, the objective response rates and overall survival, and the severity of the patients side effects. The objective response rates are a measure of the amount of patients who experienced a predetermined tumor size reduction. The durable response rates measure the duration of positive responses in patients. [9] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519012/pdf/nihms709872.pdf


By Alex Fazioli



Double brackets: [[
Filename: PHIL_1181_lores.jpg
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit: Electron micrograph of the Ebola Zaire virus. This was the first photo ever taken of the virus, on 10/13/1976. By Dr. F.A. Murphy, now at U.C. Davis, then at the CDC.
Closed double brackets: ]]

Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+

Section 2

Include some current research, with at least one figure showing data.

Section 3

Include some current research, with at least one figure showing data.

Section 4

Conclusion

References


1. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Milhem, M. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of clinical oncology, 33(25), 2780-2788. <https://s3.amazonaws.com/academia.edu.documents/41260637/Talimogene_Laherparepvec_Improves_Durabl20160115-22239-yubl2z.pdf?AWSAccessKeyId=AKIAIWOWYYGZ2Y53UL3A&Expires=1522701871&Signature=rttGQ7Dqvp0CPvJGeXHU5jkWlU4%3D&response-content-disposition=inline%3B%20filename%3DTalimogene_Laherparepvec_Improves_Durabl.pdf>.

2. Pol, J., Kroemer, G., & Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy. Oncoimmuneology, 5(1), e1115641 (3 pages). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760283/>.

3. Liu, B. L., Robinson, M., Han, Z., Branston, R. H., English, C., Reay, P., & ... Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 10(4), 292. <https://www.nature.com/articles/3301885>.

9. Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015). Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy , 7(6), 611-619. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519012/pdf/nihms709872.pdf>





Authored for BIOL 238 Microbiology, taught by Joan Slonczewski, 2018, Kenyon College.